If Wall Street was looking for a biotech deal that would validate the sector's lofty valuation and provide more fuel for the recent rally, Monday's merger of Idec Pharmaceuticals (IDPH) and Biogen (BGEN) probably isn't it.That's not to say the $6.5 billion
Editor's Note: Interested in learning more about biotech? Attend an interactive chat Wednesday, June 25 with RealMoney columnist Adam Feuerstein to learn the five things you need to know before buying a biotech stock -- and also to ask questions of Adam. Tune in to chat about this hot sector! Click here for more information and to sign up.